Literature DB >> 31941709

MYC Instructs and Maintains Pancreatic Adenocarcinoma Phenotype.

Valentin J A Barthet1, Tania Campos1, Nicole M Sodir1, Roderik M Kortlever1, Luca Pellegrinet1, Steven Kupczak2, Panayiotis Anastasiou1, Lamorna Brown Swigart3, Laura Soucek4, Mark J Arends5, Trevor D Littlewood1, Gerard I Evan6.   

Abstract

The signature features of pancreatic ductal adenocarcinoma (PDAC) are its fibroinflammatory stroma, poor immune activity, and dismal prognosis. We show that acute activation of Myc in indolent pancreatic intraepithelial neoplasm (PanIN) epithelial cells in vivo is, alone, sufficient to trigger immediate release of instructive signals that together coordinate changes in multiple stromal and immune-cell types and drive transition to pancreatic adenocarcinomas that share all the characteristic stromal features of their spontaneous human counterpart. We also demonstrate that this Myc-driven PDAC switch is completely and immediately reversible: Myc deactivation/inhibition triggers meticulous disassembly of advanced PDAC tumor and stroma and concomitant death of tumor cells. Hence, both the formation and deconstruction of the complex PDAC phenotype are continuously dependent on a single, reversible Myc switch. SIGNIFICANCE: We show that Myc activation in indolent Kras G12D-induced PanIN epithelium acts as an immediate pleiotropic switch, triggering tissue-specific signals that instruct all the diverse signature stromal features of spontaneous human PDAC. Subsequent Myc deactivation or inhibition immediately triggers a program that coordinately disassembles PDAC back to PanIN.See related commentary by English and Sears, p. 495. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 31941709     DOI: 10.1158/2159-8290.CD-19-0435

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  44 in total

Review 1.  How Tumor Cell Dedifferentiation Drives Immune Evasion and Resistance to Immunotherapy.

Authors:  Jinyang Li; Ben Z Stanger
Journal:  Cancer Res       Date:  2020-06-18       Impact factor: 12.701

2.  Methods for Determining Myc-Induced Apoptosis.

Authors:  Dan Lu; Catherine Wilson; Trevor D Littlewood
Journal:  Methods Mol Biol       Date:  2021

3.  Deconstructing Pancreatic Adenocarcinoma by Targeting the Conductor, MYC.

Authors:  Isabel A English; Rosalie C Sears
Journal:  Cancer Discov       Date:  2020-04       Impact factor: 39.397

Review 4.  Harnessing metabolic dependencies in pancreatic cancers.

Authors:  Joel Encarnación-Rosado; Alec C Kimmelman
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-03-19       Impact factor: 46.802

5.  Epigenetic and Transcriptional Control of the Epidermal Growth Factor Receptor Regulates the Tumor Immune Microenvironment in Pancreatic Cancer.

Authors:  Jinyang Li; Salina Yuan; Robert J Norgard; Fangxue Yan; Yu H Sun; Il-Kyu Kim; Allyson J Merrell; Yogev Sela; Yanqing Jiang; Natarajan V Bhanu; Benjamin A Garcia; Robert H Vonderheide; Andrés Blanco; Ben Z Stanger
Journal:  Cancer Discov       Date:  2020-11-06       Impact factor: 39.397

6.  MYC- and MIZ1-Dependent Vesicular Transport of Double-Strand RNA Controls Immune Evasion in Pancreatic Ductal Adenocarcinoma.

Authors:  Bastian Krenz; Anneli Gebhardt-Wolf; Carsten P Ade; Abdallah Gaballa; Florian Roehrig; Emilia Vendelova; Apoorva Baluapuri; Ursula Eilers; Peter Gallant; Luana D'Artista; Armin Wiegering; Georg Gasteiger; Mathias T Rosenfeldt; Stefan Bauer; Lars Zender; Elmar Wolf; Martin Eilers
Journal:  Cancer Res       Date:  2021-06-18       Impact factor: 12.701

Review 7.  KRAS Mutation Dictates the Cancer Immune Environment in Pancreatic Ductal Adenocarcinoma and Other Adenocarcinomas.

Authors:  Meichen Gu; Yanli Gao; Pengyu Chang
Journal:  Cancers (Basel)       Date:  2021-05-18       Impact factor: 6.639

Review 8.  Diversity and Biology of Cancer-Associated Fibroblasts.

Authors:  Giulia Biffi; David A Tuveson
Journal:  Physiol Rev       Date:  2020-05-28       Impact factor: 37.312

9.  Immunity-Related Gene Signature Identifies Subtypes Benefitting From Adjuvant Chemotherapy or Potentially Responding to PD1/PD-L1 Blockage in Pancreatic Cancer.

Authors:  Hao Qian; Hongzhe Li; Junjie Xie; Xiongxiong Lu; Fanlu Li; Weishen Wang; Xiaomei Tang; Minmin Shi; Linxi Jiang; Hongwei Li; Hao Chen; Chenghong Peng; Zhiwei Xu; Xiaxing Deng; Baiyong Shen
Journal:  Front Cell Dev Biol       Date:  2021-06-23

10.  Repression of the Type I Interferon Pathway Underlies MYC- and KRAS-Dependent Evasion of NK and B Cells in Pancreatic Ductal Adenocarcinoma.

Authors:  Nathiya Muthalagu; Tiziana Monteverde; Ximena Raffo-Iraolagoitia; Robert Wiesheu; Declan Whyte; Ann Hedley; Sarah Laing; Björn Kruspig; Rosanna Upstill-Goddard; Robin Shaw; Sarah Neidler; Curtis Rink; Saadia A Karim; Katarina Gyuraszova; Colin Nixon; William Clark; Andrew V Biankin; Leo M Carlin; Seth B Coffelt; Owen J Sansom; Jennifer P Morton; Daniel J Murphy
Journal:  Cancer Discov       Date:  2020-03-21       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.